Vericel Corporation (NASDAQ: VCEL) Stock Competitors & Peer Comparison
See VCEL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VCEL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VCEL | $39.55 | -1.17% | 2B | 84.15 | $0.47 | N/A |
| VRTX | $510.72 | +0.47% | 129.6B | 26.83 | $19.03 | N/A |
| REGN | $798.17 | +1.70% | 82.2B | 17.49 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| MRNA | $172.94 | +12.27% | 68.6B | -21.22 | -$8.15 | N/A |
| ARGX | $988.20 | -0.21% | 61.5B | 35.63 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $192.76 | +0.95% | 41B | -21.85 | -$8.82 | N/A |
| RVMDW | $9.98 | +3.47% | 39.3B | -1.13 | -$8.82 | N/A |
| ONC | $365.67 | +4.23% | 39.1B | 64.38 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
VCEL vs VRTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, VRTX has a market cap of 129.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while VRTX trades at $510.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas VRTX's P/E ratio is 26.83. In terms of profitability, VCEL's ROE is +0.07%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, VCEL is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
VCEL vs REGN Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, REGN has a market cap of 82.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while REGN trades at $798.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas REGN's P/E ratio is 17.49. In terms of profitability, VCEL's ROE is +0.07%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
VCEL vs VRNA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VCEL's ROE is +0.07%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, VCEL is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check VRNA's competition here
Moderna, Inc. (NASDAQ: MRNA)
VCEL vs MRNA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MRNA has a market cap of 68.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MRNA trades at $172.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MRNA's P/E ratio is -21.22. In terms of profitability, VCEL's ROE is +0.07%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VCEL is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check MRNA's competition here
argenx SE (NASDAQ: ARGX)
VCEL vs ARGX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ARGX has a market cap of 61.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ARGX trades at $988.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ARGX's P/E ratio is 35.63. In terms of profitability, VCEL's ROE is +0.07%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, VCEL is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
VCEL vs SGEN Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VCEL's ROE is +0.07%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VCEL is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
VCEL vs RVMD Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RVMD trades at $192.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RVMD's P/E ratio is -21.85. In terms of profitability, VCEL's ROE is +0.07%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, VCEL is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
VCEL vs RVMDW Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RVMDW has a market cap of 39.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RVMDW trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RVMDW's P/E ratio is -1.13. In terms of profitability, VCEL's ROE is +0.07%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, VCEL is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
VCEL vs ONC Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ONC has a market cap of 39.1B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ONC trades at $365.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ONC's P/E ratio is 64.38. In terms of profitability, VCEL's ROE is +0.07%, compared to ONC's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
VCEL vs ALNY Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ALNY has a market cap of 32.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ALNY trades at $244.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ALNY's P/E ratio is 44.02. In terms of profitability, VCEL's ROE is +0.07%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VCEL is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
VCEL vs ROIV Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ROIV has a market cap of 28.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ROIV trades at $38.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ROIV's P/E ratio is -37.09. In terms of profitability, VCEL's ROE is +0.07%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, VCEL is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
VCEL vs INSM Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, INSM has a market cap of 26.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while INSM trades at $121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas INSM's P/E ratio is -29.44. In terms of profitability, VCEL's ROE is +0.07%, compared to INSM's ROE of -1.11%. Regarding short-term risk, VCEL is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
VCEL vs INCY Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, INCY has a market cap of 25.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while INCY trades at $124.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas INCY's P/E ratio is 16.75. In terms of profitability, VCEL's ROE is +0.07%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VCEL is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
VCEL vs BNTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, BNTX has a market cap of 24.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while BNTX trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas BNTX's P/E ratio is -12.71. In terms of profitability, VCEL's ROE is +0.07%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, VCEL is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
VCEL vs GMAB Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while GMAB trades at $34.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas GMAB's P/E ratio is 26.14. In terms of profitability, VCEL's ROE is +0.07%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
VCEL vs UTHR Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, UTHR has a market cap of 20.9B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while UTHR trades at $493.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas UTHR's P/E ratio is 17.64. In terms of profitability, VCEL's ROE is +0.07%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, VCEL is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
VCEL vs BGNE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VCEL's ROE is +0.07%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, VCEL is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
VCEL vs DNA-WT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VCEL's ROE is +0.07%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, VCEL is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
VCEL vs JAZZ Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while JAZZ trades at $241.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, VCEL's ROE is +0.07%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, VCEL is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
VCEL vs ASND Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ASND trades at $237.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ASND's P/E ratio is -98.18. In terms of profitability, VCEL's ROE is +0.07%, compared to ASND's ROE of +1.90%. Regarding short-term risk, VCEL is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
VCEL vs NBIX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while NBIX trades at $143.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas NBIX's P/E ratio is 20.80. In terms of profitability, VCEL's ROE is +0.07%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VCEL is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
VCEL vs EXEL Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, EXEL has a market cap of 14.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while EXEL trades at $57.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas EXEL's P/E ratio is 16.35. In terms of profitability, VCEL's ROE is +0.07%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, VCEL is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
VCEL vs SMMT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while SMMT trades at $16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas SMMT's P/E ratio is -15.09. In terms of profitability, VCEL's ROE is +0.07%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VCEL is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
VCEL vs HALO Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while HALO trades at $111.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas HALO's P/E ratio is 20.79. In terms of profitability, VCEL's ROE is +0.07%, compared to HALO's ROE of +1.81%. Regarding short-term risk, VCEL is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
VCEL vs BBIO Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while BBIO trades at $66.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas BBIO's P/E ratio is -17.80. In terms of profitability, VCEL's ROE is +0.07%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, VCEL is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
VCEL vs KRTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VCEL's ROE is +0.07%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VCEL is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
VCEL vs BMRN Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while BMRN trades at $64.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas BMRN's P/E ratio is 30.80. In terms of profitability, VCEL's ROE is +0.07%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, VCEL is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
VCEL vs MDGL Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MDGL trades at $521.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MDGL's P/E ratio is -40.78. In terms of profitability, VCEL's ROE is +0.07%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VCEL is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
VCEL vs TECH Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TECH trades at $72.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TECH's P/E ratio is 37.36. In terms of profitability, VCEL's ROE is +0.07%, compared to TECH's ROE of +0.09%. Regarding short-term risk, VCEL is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
VCEL vs RNAM Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VCEL's ROE is +0.07%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VCEL is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
VCEL vs AXSM Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while AXSM trades at $205.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas AXSM's P/E ratio is -53.65. In terms of profitability, VCEL's ROE is +0.07%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, VCEL is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
VCEL vs TWST Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TWST has a market cap of 10.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TWST trades at $165.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TWST's P/E ratio is -74.69. In terms of profitability, VCEL's ROE is +0.07%, compared to TWST's ROE of -0.30%. Regarding short-term risk, VCEL is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check TWST's competition here
10x Genomics, Inc. (NASDAQ: TXG)
VCEL vs TXG Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TXG has a market cap of 10B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TXG trades at $79.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TXG's P/E ratio is -134.07. In terms of profitability, VCEL's ROE is +0.07%, compared to TXG's ROE of -0.09%. Regarding short-term risk, VCEL is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
VCEL vs KRYS Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while KRYS trades at $333.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas KRYS's P/E ratio is 41.84. In terms of profitability, VCEL's ROE is +0.07%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VCEL is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check KRYS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
VCEL vs ARWR Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ARWR has a market cap of 9.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ARWR trades at $68.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ARWR's P/E ratio is -30.57. In terms of profitability, VCEL's ROE is +0.07%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, VCEL is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
VCEL vs KYMR Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while KYMR trades at $117.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas KYMR's P/E ratio is -36.77. In terms of profitability, VCEL's ROE is +0.07%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, VCEL is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
VCEL vs RXDX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VCEL's ROE is +0.07%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VCEL is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
VCEL vs PTGX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while PTGX trades at $144.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas PTGX's P/E ratio is 140.76. In terms of profitability, VCEL's ROE is +0.07%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, VCEL is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
VCEL vs NUVL Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VCEL's ROE is +0.07%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VCEL is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
VCEL vs CRNX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CRNX's P/E ratio is -16.86. In terms of profitability, VCEL's ROE is +0.07%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VCEL is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
VCEL vs IBRX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while IBRX trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas IBRX's P/E ratio is -8.71. In terms of profitability, VCEL's ROE is +0.07%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, VCEL is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
VCEL vs TGTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TGTX trades at $57.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TGTX's P/E ratio is 20.71. In terms of profitability, VCEL's ROE is +0.07%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, VCEL is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check TGTX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
VCEL vs IMGN Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VCEL's ROE is +0.07%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VCEL is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
VCEL vs CAI Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CAI trades at $30.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CAI's P/E ratio is 86.12. In terms of profitability, VCEL's ROE is +0.07%, compared to CAI's ROE of +0.19%. Regarding short-term risk, VCEL is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
VCEL vs PCVX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while PCVX trades at $58.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas PCVX's P/E ratio is -7.72. In terms of profitability, VCEL's ROE is +0.07%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, VCEL is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PCVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
VCEL vs CYTK Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CYTK trades at $67.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CYTK's P/E ratio is -9.36. In terms of profitability, VCEL's ROE is +0.07%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, VCEL is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check CYTK's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
VCEL vs BPMC Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VCEL's ROE is +0.07%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VCEL is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
VCEL vs APGE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas APGE's P/E ratio is -31.19. In terms of profitability, VCEL's ROE is +0.07%, compared to APGE's ROE of -0.30%. Regarding short-term risk, VCEL is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
VCEL vs PRAX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while PRAX trades at $298.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas PRAX's P/E ratio is -23.11. In terms of profitability, VCEL's ROE is +0.07%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, VCEL is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
VCEL vs CERE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CERE's P/E ratio is -16.47. In terms of profitability, VCEL's ROE is +0.07%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VCEL is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
VCEL vs SYRE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, SYRE has a market cap of 8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while SYRE trades at $92.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas SYRE's P/E ratio is -47.19. In terms of profitability, VCEL's ROE is +0.07%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, VCEL is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
VCEL vs IMVT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while IMVT trades at $37.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas IMVT's P/E ratio is -13.18. In terms of profitability, VCEL's ROE is +0.07%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, VCEL is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check IMVT's competition here
Abivax S.A. (NASDAQ: ABVX)
VCEL vs ABVX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ABVX trades at $103.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ABVX's P/E ratio is -19.69. In terms of profitability, VCEL's ROE is +0.07%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VCEL is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
VCEL vs IONS Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while IONS trades at $44.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas IONS's P/E ratio is -13.73. In terms of profitability, VCEL's ROE is +0.07%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VCEL is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check IONS's competition here
Metsera, Inc. (NASDAQ: MTSR)
VCEL vs MTSR Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VCEL's ROE is +0.07%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VCEL is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MTSR's competition here
Belite Bio, Inc (NASDAQ: BLTE)
VCEL vs BLTE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while BLTE trades at $173.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas BLTE's P/E ratio is -92.73. In terms of profitability, VCEL's ROE is +0.07%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, VCEL is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
VCEL vs CGON Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CGON trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CGON's P/E ratio is -29.09. In terms of profitability, VCEL's ROE is +0.07%, compared to CGON's ROE of -0.25%. Regarding short-term risk, VCEL is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
VCEL vs MRUS Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VCEL's ROE is +0.07%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VCEL is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
VCEL vs RYTM Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RYTM trades at $98.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RYTM's P/E ratio is -31.78. In terms of profitability, VCEL's ROE is +0.07%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, VCEL is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
VCEL vs ACLX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VCEL's ROE is +0.07%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VCEL is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
VCEL vs RETA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RETA's P/E ratio is -66.29. In terms of profitability, VCEL's ROE is +0.07%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VCEL is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
VCEL vs CNTA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VCEL's ROE is +0.07%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VCEL is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
VCEL vs TVTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TVTX trades at $62.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TVTX's P/E ratio is -139.69. In terms of profitability, VCEL's ROE is +0.07%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, VCEL is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TVTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
VCEL vs LGND Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while LGND trades at $290.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas LGND's P/E ratio is 31.84. In terms of profitability, VCEL's ROE is +0.07%, compared to LGND's ROE of +0.20%. Regarding short-term risk, VCEL is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
VCEL vs SRRK Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while SRRK trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas SRRK's P/E ratio is -13.96. In terms of profitability, VCEL's ROE is +0.07%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, VCEL is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check SRRK's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
VCEL vs ORKA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ORKA trades at $93.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ORKA's P/E ratio is -48.13. In terms of profitability, VCEL's ROE is +0.07%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, VCEL is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ORKA's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
VCEL vs CRSP Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CRSP trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CRSP's P/E ratio is -12.25. In terms of profitability, VCEL's ROE is +0.07%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, VCEL is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check CRSP's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
VCEL vs CDTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VCEL's ROE is +0.07%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VCEL is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
VCEL vs MIRM Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MIRM trades at $92.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MIRM's P/E ratio is -6.32. In terms of profitability, VCEL's ROE is +0.07%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, VCEL is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check MIRM's competition here
Abcam plc (NASDAQ: ABCM)
VCEL vs ABCM Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VCEL's ROE is +0.07%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VCEL is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
VCEL vs ISEE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VCEL's ROE is +0.07%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VCEL is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
VCEL vs COGT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while COGT trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas COGT's P/E ratio is -15.17. In terms of profitability, VCEL's ROE is +0.07%, compared to COGT's ROE of -0.73%. Regarding short-term risk, VCEL is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
VCEL vs PTCT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while PTCT trades at $65.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas PTCT's P/E ratio is -28.01. In terms of profitability, VCEL's ROE is +0.07%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VCEL is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check PTCT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
VCEL vs DNTH Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while DNTH trades at $96.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas DNTH's P/E ratio is -23.25. In terms of profitability, VCEL's ROE is +0.07%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, VCEL is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DNTH's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
VCEL vs APLS Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas APLS's P/E ratio is 38.35. In terms of profitability, VCEL's ROE is +0.07%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VCEL is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
VCEL vs ERAS Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ERAS trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ERAS's P/E ratio is -16.17. In terms of profitability, VCEL's ROE is +0.07%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, VCEL is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ERAS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
VCEL vs DFTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while DFTX trades at $39.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas DFTX's P/E ratio is N/A. In terms of profitability, VCEL's ROE is +0.07%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, VCEL is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check DFTX's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
VCEL vs EWTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while EWTX trades at $44.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas EWTX's P/E ratio is -24.13. In terms of profitability, VCEL's ROE is +0.07%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, VCEL is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
VCEL vs TERN Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TERN's P/E ratio is -51.41. In terms of profitability, VCEL's ROE is +0.07%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VCEL is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check TERN's competition here
Veradermics, Incorporated (NYSE: MANE)
VCEL vs MANE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MANE trades at $112.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MANE's P/E ratio is -35.94. In terms of profitability, VCEL's ROE is +0.07%, compared to MANE's ROE of -0.38%. Regarding short-term risk, VCEL is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
VCEL vs FOLD Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VCEL's ROE is +0.07%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VCEL is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check FOLD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
VCEL vs IOVA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, IOVA has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while IOVA trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas IOVA's P/E ratio is -13.96. In terms of profitability, VCEL's ROE is +0.07%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, VCEL is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check IOVA's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
VCEL vs ACAD Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ACAD trades at $26.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ACAD's P/E ratio is 11.89. In terms of profitability, VCEL's ROE is +0.07%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, VCEL is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ACAD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
VCEL vs AKRO Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VCEL's ROE is +0.07%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VCEL is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check AKRO's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
VCEL vs ADPT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ADPT trades at $27.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ADPT's P/E ratio is -67.95. In terms of profitability, VCEL's ROE is +0.07%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, VCEL is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
VCEL vs ALPN Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VCEL's ROE is +0.07%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VCEL is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
VCEL vs PBLS Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while PBLS trades at $36.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas PBLS's P/E ratio is -19.64. In terms of profitability, VCEL's ROE is +0.07%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, VCEL is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
VCEL vs OPT Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas OPT's P/E ratio is -1.52. In terms of profitability, VCEL's ROE is +0.07%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VCEL is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
VCEL vs PRTC Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VCEL's ROE is +0.07%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VCEL is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
VCEL vs MRTX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VCEL's ROE is +0.07%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VCEL is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
VCEL vs CELC Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CELC trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CELC's P/E ratio is -19.53. In terms of profitability, VCEL's ROE is +0.07%, compared to CELC's ROE of -3.51%. Regarding short-term risk, VCEL is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
VCEL vs RLAY Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RLAY trades at $18.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RLAY's P/E ratio is -11.59. In terms of profitability, VCEL's ROE is +0.07%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, VCEL is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check RLAY's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
VCEL vs ABCL Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while ABCL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas ABCL's P/E ratio is -23.44. In terms of profitability, VCEL's ROE is +0.07%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, VCEL is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
VCEL vs CPRX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CPRX's P/E ratio is 12.30. In terms of profitability, VCEL's ROE is +0.07%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VCEL is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CPRX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
VCEL vs TLX Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while TLX trades at $11.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas TLX's P/E ratio is 118.06. In terms of profitability, VCEL's ROE is +0.07%, compared to TLX's ROE of +0.07%. Regarding short-term risk, VCEL is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check TLX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
VCEL vs XENE Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while XENE trades at $38.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas XENE's P/E ratio is -8.30. In terms of profitability, VCEL's ROE is +0.07%, compared to XENE's ROE of -0.44%. Regarding short-term risk, VCEL is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for VCEL.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
VCEL vs RYZB Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VCEL's ROE is +0.07%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VCEL is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
VCEL vs CBAY Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VCEL's ROE is +0.07%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VCEL is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check CBAY's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
VCEL vs IDYA Comparison September 2026
Vericel Corporation (NASDAQ: VCEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VCEL stands at 2B. In comparison, IDYA has a market cap of 3.7B. Regarding current trading prices, VCEL is priced at $39.55 on the NASDAQ, while IDYA trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VCEL currently has a P/E ratio of 84.15, whereas IDYA's P/E ratio is -20.03. In terms of profitability, VCEL's ROE is +0.07%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, VCEL is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for VCEL.Check IDYA's competition here